Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Cancer Vaccines Market 2021
25 June 2021
The global cancer vaccines market is set to grow by US$ 3 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 8.2% during the forecast period, according to data and analytics company StrategyHelix. Increase in prevalence of cancer worldwide, rising investments and government funding in the development of cancer vaccines, rise in development of new cancer vaccines, launch and approval of new cancer vaccines in the market are expected to boost the market growth in the coming years.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for cancer vaccines. The global cancer vaccines market is segmented on the basis of product, application, technology, and region. By product, it is categorized into preventative vaccines, and therapeutic vaccines. The preventative vaccines segment held the largest market share in 2020. By application, the cancer vaccines market is divided into cervical cancer, liver cancer, prostate cancer, and others. The cervical cancer segment accounted for the largest market share in 2020. Based on technology, the cancer vaccines market is divided into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines.
The report has profiled some of the key players of the market such as Amgen Inc., Anixa Biosciences Inc. (ANIX), Dendreon Corporation, Dendreon Pharmaceuticals LLC, eTheRNA immunotherapies NV, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Immunicum AB, Inovio Pharmaceuticals Inc., Merck KGaA, Moderna Inc., OSE Immunotherapeutics SA, Providence Therapeutics Holdings Inc., Sanofi SA, UbiVac Inc., Vaccinogen Inc..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the cancer vaccines market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Product: preventative vaccines, and therapeutic vaccines
Application: cervical cancer, liver cancer, prostate cancer, and others
Technology: dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines
Region: North America, Asia Pacific, Europe, and Rest of the World (ROW)
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the global cancer vaccines market
Identify regional strategies and strategic priorities on the basis of local data and analysis
Pinpoint growth sectors and trends for investment
Understand what the future of the global cancer vaccines market looks like
Identify the competitive landscape and window of opportunity
Table of Contents
1. Market Definition
2. Research Methodology
3. Market Data & Outlook
3.1 Market Value
3.2 Market Value Forecast
4. Cancer Vaccines Market by Product
4.1 Preventative Vaccines
4.2 Therapeutic Vaccines
5. Cancer Vaccines Market by Application
5.1 Cervical Cancer
5.2 Liver Cancer
5.3 Prostate Cancer
6. Cancer Vaccines Market by Technology
6.1 Dendritic Cells (Dc) Cancer Vaccines
6.2 Recombinant Cancer Vaccines
6.3 Antigen/Adjuvant Cancer Vaccines
6.4 Viral Vector & Dna Cancer Vaccines
7. Cancer Vaccines Market by Region
7.1 North America
7.2 Asia Pacific
7.4 Rest Of The World (Row)
8. Company Profiles
8.1 Amgen Inc.
8.2 Anixa Biosciences, Inc. (ANIX)
8.3 Dendreon Corporation
8.4 Dendreon Pharmaceuticals LLC
8.5 eTheRNA immunotherapies NV
8.6 F. Hoffmann-La Roche Ltd.
8.7 GlaxoSmithKline plc
8.8 Immunicum AB
8.9 Inovio Pharmaceuticals, Inc.
8.10 Merck KGaA
8.11 Moderna, Inc.
8.12 OSE Immunotherapeutics SA
8.13 Providence Therapeutics Holdings Inc.
8.14 Sanofi SA
8.15 UbiVac, Inc.
8.16 Vaccinogen Inc.
9.1 About StrategyHelix